Table 1.
Baseline characteristics of study participants by ETV6/RUNX1 status classification.
| Characteristics | Total | ETV6/RUNX1 status | P value | |
|---|---|---|---|---|
| Negative (n = 2,069) | Positive (n = 461) | |||
| Gender, n (%) | 0.852 | |||
| Male | 1,472 (58.2%) | 1,202 (58.1%) | 270 (58.6%) | |
| Female | 1,058 (41.8%) | 867 (41.9%) | 191 (41.4%) | |
| Age (y), median (range) | 4.3 (0.1–17.4) | 4.4 (0.1–17.4) | 4.2(0.8–14.2) | 0.365 |
| Age group (y) | <0.001 | |||
| ≥1, <10 | 2,176 (86.0%) | 1,740 (84.1%) | 436 (94.6%) | |
| ≥10 or <1 | 354 (14.0%) | 329 (15.9%) | 25 (5.4%) | |
| Chemotherapy protocol, n (%) | 0.279 | |||
| SCCLG-ALL-2016 Protocol | 1,549 (61.2%) | 1,277 (61.7%) | 272 (59.0%) | |
| GD-ALL-2008 Protocol | 981 (38.8%) | 792 (38.3%) | 189 (41.0%) | |
| Initial WBC (×109/L), median (range) | 9.3 (0.1–1,095.0) | 9.6 (0.2–1,095.0) | 8.6 (0.1–268.5) | 0.099 |
| WBC group, n (%) | <0.001 | |||
| <10×109/L | 1,306 (51.7%) | 1,047 (50.7%) | 259 (56.2%) | |
| ≥10×109/L, <50×109/L | 784 (31.0%) | 633 (30.7%) | 151 (32.8%) | |
| ≥50×109/L | 436 (17.3%) | 385 (18.6%) | 51 (11.1%) | |
| Initial Hb (g/L), median (range) | 76 (16–182.0) | 77.0 (17–182.0) | 73.5 (16.0–145.0) | <0.001 |
| Hb group | <0.001 | |||
| <60 g/L | 530 (21.0%) | 417 (20.2%) | 113 (24.6%) | |
| ≥60 g/L, <90 g/L | 1,281 (50.8%) | 1,028 (49.9%) | 253 (55.0%) | |
| ≥90 g/L, <110 g/L | 507 (20.1%) | 427 (20.7%) | 80 (17.4%) | |
| ≥110 g/L | 204 (8.1%) | 190 (9.2%) | 14 (3.0%) | |
| Initial PLT (×109/L), median (range) | 53.0 (0.0–784.0) | 90.0 (101.5) 53.0 (0.0–784.0) | 75.0 (74.8) 52.0 (2.0–539.0) | 0.190 |
| PLT group | 0.007 | |||
| <100×109/L | 1,809 (71.7%) | 1,464 (70.9%) | 345 (75.0%) | |
| ≥100, <300×109/L | 597 (23.7%) | 491 (23.8%) | 106 (23.0%) | |
| ≥300×109/L | 118 (4.7%) | 109 (5.3%) | 9 (2.0%) | |
| Risk group, n (%) | <0.001 | |||
| SR | 674 (26.6%) | 508 (24.6%) | 166 (36.0%) | |
| IR | 1,302 (51.5%) | 1,052 (50.8%) | 250 (54.2%) | |
| HR | 554 (21.9%) | 509 (24.6%) | 45 (9.8%) | |
| Immunophenotype, n (%) | 0.09 | |||
| Pro-B | 131 (5.2%) | 112 (5.4%) | 19 (4.1%) | |
| Common-B | 1,722 (68.1%) | 1,392 (67.3%) | 330 (71.6%) | |
| Pre-B | 161 (6.4%) | 127 (6.1%) | 34 (7.4%) | |
| Immature-B | 516 (20.4%) | 438 (21.2%) | 78 (16.9%) | |
| CNSL, n (%) | 0.193 | |||
| Yes | 79 (3.1%) | 69 (3.3%) | 10 (2.2%) | |
| No | 2,451 (96.9%) | 2,000 (96.7%) | 451 (97.8%) | |
| BCR/ABL1 Status, n (%) | <0.001 | |||
| Negative | 2,390 (94.6%) | 1,936 (93.6%) | 454 (98.9%) | |
| Positive | 137 (5.4%) | 132 (6.4%) | 5 (1.1%) | |
| MLL-r Status, n (%) | 0.018 | |||
| Negative | 2,436 (96.4%) | 1,985 (96.0%) | 451 (98.3%) | |
| Positive | 91 (3.6%) | 83 (4.0%) | 8 (1.7%) | |
| E2A/PBX1 Status, n (%) | <0.001 | |||
| Negative | 2,391 (94.5%) | 1,935 (93.5%) | 456 (98.9%) | |
| Positive | 139 (5.5%) | 134 (6.5%) | 5 (1.1%) | |
| Prednisone Response, n (%) | <0.001 | |||
| PGR | 2,314 (92.1%) | 1,871 (91.0%) | 443 (96.9%) | |
| PPR | 198 (7.9%) | 184 (9.0%) | 14 (3.1%) | |
| D15 BM, n (%) | 0.788 | |||
| M1 | 1,880 (78.1%) | 1,540 (78.2%) | 340 (77.6%) | |
| M2/M3 | 527 (21.9%) | 429 (21.8%) | 98 (22.4%) | |
| D33 BM, n (%) | 0.004 | |||
| M1 | 2,394 (98.1%) | 1,948 (97.7%) | 446 (99.8%) | |
| M2/M3 | 47 (1.9%) | 46 (2.3%) | 1 (0.2%) | |
| D15 MRD, n (%) | 0.165 | |||
| <0.1% | 712 (40.8%) | 573 (40.0%) | 139 (44.3%) | |
| ≥0.1% | 1,034 (59.2%) | 859 (60.0%) | 175 (55.7%) | |
| D33 MRD, n (%) | 0.01 | |||
| <0.01% | 1,441 (83.8%) | 1,167 (82.7%) | 274 (88.7%) | |
| ≥0.01% | 279 (16.2%) | 244 (17.3%) | 35 (11.3%) | |
WBC, white blood cell counts; Hb, hemoglobin; PLT, platelet; CNSL, central nervous system leukemia; MLL-r, MLL rearrangement; BM, bone marrow; MRD, minimal residual disease.